Viatris' phase 3 trial of pimecrolimus 0.3% (MR-139) for blepharitis fails to meet primary end point
Published on July 23, 2025
The solution missed the primary end point of the trial, which was complete resolution of debris after 6 weeks of twice-daily dosing.